FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311101253> ?p ?o ?g. }

• W4311101253 abstract "Abstract Background Recent evidences from clinical trials ( NCT04486911 ) revealed that the combination of pyrotinib, letrozole and dalpiciclib exerted optimistic therapeutic effect to treat HER2 + HR + breast cancer, however, the underlying molecular mechanism remained further investigation. Methods Through the drug sensitivity test, the drug combination efficacy of pyrotinib, tamoxifen and dalpiciclib to BT474 cells were tested. The underlying molecular mechanisms were investigated using immunofluorescence, western blot analysis, immunohistochemical staining and cell cycle analysis. Potential risk factor which may indicate the responsiveness to drug treatment in HER2 + /HR + breast cancer was selected out using RNA-sequence and tested using immunohistochemical staining and in vivo drug susceptibility test. Results We found that pyrotinib combined with dalpiciclib exerted better cytotoxic efficacy than pyrotinib combined with tamoxifen in BT474 cells. Degradation of HER2 could enhance ER nuclear transportation, activating ER signaling pathway in BT474 cells whereas dalpiciclib could partially abrogate this process. This may be the underlying mechanism by which combination of pyrotinib, tamoxifen and dalpiciclib exerted best cytotoxic effect. Furthermore, CALML5 was revealed to be a risk factor in the treatment of HER2 + /HR + breast cancer and the usage of dalpiciclib might overcome this. Conclusion Our study provided evidence that the usage of dalpiciclib in the treatment of HER2 + /HR + breast cancer could partially abrogate the estrogen signaling pathway activation caused by anti-HER2 therapy and revealed that CALML5 could serve as a risk factor in the treatment of HER2 + /HR + breast cancer. Funding This study was supported by the National Natural Science Foundation of China (#U20A20381, #81872159)" @default.
• W4311101253 created "2022-12-23" @default.
• W4311101253 creator A5000989655 @default.
• W4311101253 creator A5005319473 @default.
• W4311101253 creator A5005974424 @default.
• W4311101253 creator A5017658063 @default.
• W4311101253 creator A5026107610 @default.
• W4311101253 creator A5029148942 @default.
• W4311101253 creator A5040247437 @default.
• W4311101253 creator A5042007093 @default.
• W4311101253 creator A5052629282 @default.
• W4311101253 creator A5054771846 @default.
• W4311101253 creator A5058380236 @default.
• W4311101253 creator A5066981358 @default.
• W4311101253 creator A5070293749 @default.
• W4311101253 date "2022-12-11" @default.
• W4311101253 modified "2023-10-17" @default.
• W4311101253 title "Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2⁺HR⁺Breast Cancer" @default.
• W4311101253 cites W1964685026 @default.
• W4311101253 cites W1997381761 @default.
• W4311101253 cites W2057808719 @default.
• W4311101253 cites W2075894019 @default.
• W4311101253 cites W2076326365 @default.
• W4311101253 cites W2077945404 @default.
• W4311101253 cites W2095861620 @default.
• W4311101253 cites W2097255042 @default.
• W4311101253 cites W2123591186 @default.
• W4311101253 cites W2129060478 @default.
• W4311101253 cites W2141393790 @default.
• W4311101253 cites W2143651667 @default.
• W4311101253 cites W2145657357 @default.
• W4311101253 cites W2162982444 @default.
• W4311101253 cites W2299045691 @default.
• W4311101253 cites W2340698646 @default.
• W4311101253 cites W2588881638 @default.
• W4311101253 cites W2591900900 @default.
• W4311101253 cites W2782896696 @default.
• W4311101253 cites W2914556350 @default.
• W4311101253 cites W3006652814 @default.
• W4311101253 cites W3024282827 @default.
• W4311101253 cites W3087175944 @default.
• W4311101253 cites W3183953444 @default.
• W4311101253 cites W4254815115 @default.
• W4311101253 cites W4309235575 @default.
• W4311101253 doi "https://doi.org/10.1101/2022.12.07.519433" @default.
• W4311101253 hasPublicationYear "2022" @default.
• W4311101253 type Work @default.
• W4311101253 citedByCount "0" @default.
• W4311101253 crossrefType "posted-content" @default.
• W4311101253 hasAuthorship W4311101253A5000989655 @default.
• W4311101253 hasAuthorship W4311101253A5005319473 @default.
• W4311101253 hasAuthorship W4311101253A5005974424 @default.
• W4311101253 hasAuthorship W4311101253A5017658063 @default.
• W4311101253 hasAuthorship W4311101253A5026107610 @default.
• W4311101253 hasAuthorship W4311101253A5029148942 @default.
• W4311101253 hasAuthorship W4311101253A5040247437 @default.
• W4311101253 hasAuthorship W4311101253A5042007093 @default.
• W4311101253 hasAuthorship W4311101253A5052629282 @default.
• W4311101253 hasAuthorship W4311101253A5054771846 @default.
• W4311101253 hasAuthorship W4311101253A5058380236 @default.
• W4311101253 hasAuthorship W4311101253A5066981358 @default.
• W4311101253 hasAuthorship W4311101253A5070293749 @default.
• W4311101253 hasBestOaLocation W43111012531 @default.
• W4311101253 hasConcept C104317684 @default.
• W4311101253 hasConcept C121608353 @default.
• W4311101253 hasConcept C126322002 @default.
• W4311101253 hasConcept C143998085 @default.
• W4311101253 hasConcept C185592680 @default.
• W4311101253 hasConcept C204232928 @default.
• W4311101253 hasConcept C2776415932 @default.
• W4311101253 hasConcept C2777176818 @default.
• W4311101253 hasConcept C2778812593 @default.
• W4311101253 hasConcept C502942594 @default.
• W4311101253 hasConcept C530470458 @default.
• W4311101253 hasConcept C55493867 @default.
• W4311101253 hasConcept C62478195 @default.
• W4311101253 hasConcept C71924100 @default.
• W4311101253 hasConcept C84606932 @default.
• W4311101253 hasConcept C98274493 @default.
• W4311101253 hasConceptScore W4311101253C104317684 @default.
• W4311101253 hasConceptScore W4311101253C121608353 @default.
• W4311101253 hasConceptScore W4311101253C126322002 @default.
• W4311101253 hasConceptScore W4311101253C143998085 @default.
• W4311101253 hasConceptScore W4311101253C185592680 @default.
• W4311101253 hasConceptScore W4311101253C204232928 @default.
• W4311101253 hasConceptScore W4311101253C2776415932 @default.
• W4311101253 hasConceptScore W4311101253C2777176818 @default.
• W4311101253 hasConceptScore W4311101253C2778812593 @default.
• W4311101253 hasConceptScore W4311101253C502942594 @default.
• W4311101253 hasConceptScore W4311101253C530470458 @default.
• W4311101253 hasConceptScore W4311101253C55493867 @default.
• W4311101253 hasConceptScore W4311101253C62478195 @default.
• W4311101253 hasConceptScore W4311101253C71924100 @default.
• W4311101253 hasConceptScore W4311101253C84606932 @default.
• W4311101253 hasConceptScore W4311101253C98274493 @default.
• W4311101253 hasLocation W43111012531 @default.
• W4311101253 hasLocation W43111012532 @default.
• W4311101253 hasOpenAccess W4311101253 @default.
• W4311101253 hasPrimaryLocation W43111012531 @default.
• W4311101253 hasRelatedWork W2072761001 @default.

• next